Micheletto Marta, Gaio Elisa, Tedesco Erik, Di Maira Giovanni, Mantovan Etienne, Zanella Michela, Pastore Paolo, Roverso Marco, Favaro Gabriella, Benetti Federico
ECSIN-European Center for the Sustainable Impact of Nanotechnology, ECAMRICERT SRL, 35127 Padova, Italy.
Department of Chemical Sciences, University of Padova, 35131 Padova, Italy.
Metabolites. 2022 May 21;12(5):463. doi: 10.3390/metabo12050463.
Iron deficiency is one of the most prevalent nutritional disorders worldwide. The standard treatment involves iron supplementation, but this task is challenging because of poor solubility and organoleptic issues. Moreover, the need to increase iron bioavailability represents a challenge for treating iron-related disorders. In this study, gastroresistance and iron intestinal absorption of an innovative granular formulation composed of ferric pyrophosphate, modified starch and phospholipids branded as Ferro Fosfosoma was investigated. Gastroresistant properties were studied using standard protocols, and a bioaccessible fraction was obtained by exposing a food supplement to in vitro digestion. This fraction was used for investigating iron absorption in Caco-2 and human follicle-associated intestinal epithelium (FAE) models. Ferro Fosfosoma showed an improved resistance to gastric digestion and higher intestinal absorption than ferric pyrophosphate salt used as a control in both models. In the FAE model, Ferro Fosfosoma induces larger iron absorption than in the Caco-2 monolayer, most likely due to the transcytosis ability of M cells. The larger iron absorption in the Ferro Fosfosoma-treated FAE model corresponds to higher ferritin level, proving physiological iron handling that was once delivered by granular formulation. Finally, the formulation did not induce any alterations in viability and barrier integrity. To conclude, Ferro Fosfosoma favors iron absorption and ferritin expression, while preserving any adverse effects.
缺铁是全球最普遍的营养失调问题之一。标准治疗方法包括补充铁剂，但由于溶解性差和感官问题，这项任务具有挑战性。此外，提高铁的生物利用度对于治疗与铁相关的疾病是一项挑战。在本研究中，对一种由焦磷酸铁、改性淀粉和磷脂组成的创新颗粒制剂（品牌为Ferro Fosfosoma）的胃耐受性和铁的肠道吸收进行了研究。使用标准方案研究胃耐受性，通过将一种食品补充剂进行体外消化获得生物可利用部分。该部分用于研究在Caco-2和人滤泡相关肠上皮（FAE）模型中的铁吸收。在两个模型中，Ferro Fosfosoma均显示出比用作对照的焦磷酸铁盐对胃消化的耐受性更好且肠道吸收更高。在FAE模型中，Ferro Fosfosoma诱导的铁吸收比在Caco-2单层中更大，这很可能是由于M细胞的转胞吞作用。在经Ferro Fosfosoma处理的FAE模型中更大的铁吸收对应于更高的铁蛋白水平，证明了颗粒制剂一旦递送后的生理性铁处理。最后，该制剂未诱导活力和屏障完整性的任何改变。总之，Ferro Fosfosoma有利于铁吸收和铁蛋白表达，同时不会产生任何不良影响。
